Urticaria and Angioedema in a COVID-19 Patient: A case of delayed presentation
Abstract
Background: COVID-19 illness can present with atypical extrapulmonary manifestations with cutaneous manifestations being one of them. Dermatological manifestations have been found in around 20.4% of cases, ranging from urticaria to vesicular rash, livedo reticularis and pseudochillblains.
Case Presentation: We present a case of 40 year old female presenting with typical COVID-19 symptoms, when she developed a urticarial rash, on 10th day of her illness followed by angioedema involving lips. Drug induced urticarial rash and other triggering factors known for urticaria were ruled out, eventual diagnosis of virus induced urticarial rash was made. She was managed with oral steroids, antihistamine agents and local lactocalmine lotion. There was complete resolution of rash within 48 hours of RT-PCR negative for COVID-19.
Conclusion and clinical Significance: This highlights the fact that COVID-19 can present with atypical manifestations and clinicians should be aware to not misdiagnose or delay the diagnosis of the disease, hence reducing the likelihood of transmission of disease.
Downloads
References
2. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118-1129.
3. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212–e213.
4. Costanzo M., De Giglio M.A.R., Roviello G.N. SARS CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020;27:4536–4541.
5. PREVAIL II Writing Group. Multi-National PREVAIL II Study Team. Davey R.T., Jr. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375(15):1448–1456.
6. Sissoko D., Laouenan C., Folkesson E. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):E1001967.
7. Mehregan DR, Hall MJ, Gibson LE.Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 1992;26:441–488
8. Dincy CVP, George R, Jacob M, et al. Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: a study from South India. J Eur Acad Dermatol Venereol 2008;22:789–794
9. Wedi B., Raap U., Wieczorek D. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5:10.
10. Galván Casas C., Català A., Carretero Hernández G. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71–77.
11. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ , van Goor H . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631–637.
12. Vaduganathan M., Vardeny O., Michel T. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–1659.
13. Cicardi M, Zuraw BL.Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract 2018;6:1132–41
14. Cohen AJ, DiFrancesco MF, Solomon SD, et al. Angioedema in COVID-19. Eur Heart J 2020; 34: 3283-3284
15. Hoffman M, Kleine-Weber H, Schroder S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–280.
This work is licensed under a Creative Commons Attribution 4.0 International License.
